Safety Shot (NASDAQ: SHOT), formerly known as Jupiter Wellness, has announced that effective today it has changed its name to Safety Shot; its ticker will also change to SHOT. The changes come after the company acquired Safety Shot, the first patented beverage that helps a person feel better faster by reducing blood alcohol content while also boosting clarity. The new beverage is currently being produced in the United States and will be available in the Q4 2023. Safety Shot is a patented beverage that helps to break down alcohol faster which aids in aiding in recovery and rehydration. Safety Shot is creating a new product category in the hangover remedies space: rapid alcohol detoxification.
“We are very excited about the opportunities ahead for our Company in the functional beverage industry,” said Safety Shot CEO Brian John in the press release. “Our management team now includes accomplished serial entrepreneurs, a former senior executive from one of the world’s largest beverage companies, and an industry leading expert in flavoring science and product formulation. We’ve created a multi-channel strategy designed to dominate e-commerce, quickly win retail shelf space, and establish longstanding ties with key distribution and sales partners in a $1.5 billion industry growing at a double-digit annual rate.”
To view the full press release, visit https://ibn.fm/KaUxm
About Safety Shot
Safety Shot, a wellness and functional beverage company, is set to launch Safety Shot, the first patented beverage on Earth that helps people feel better faster by reducing blood alcohol content and boosting clarity. The company plans to spin off legacy assets from its Jupiter Wellness business to unlock value for shareholders.
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN